Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesse Alt

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|November 22, 2012
Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosisKristen A Rahn, Crystal C Watkins, Jesse Alt, et al.
Molecular Cancer Therapeutics|October 10, 2019
The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath TumorKathryn M Lemberg, Liang Zhao, Ying Wu, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|March 14, 2019
Correction: JHU-083 selectively blocks glutaminase activity in brain CD11b<sup>+</sup> cells and prevents depression-associated behaviors induced by chronic social defeat stressXiaolei Zhu, Michael T Nedelcovych, Ajit G Thomas, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 22, 2018
JHU-083 selectively blocks glutaminase activity in brain CD11b<sup>+</sup> cells and prevents depression-associated behaviors induced by chronic social defeat stressXiaolei Zhu, Michael T Nedelcovych, Ajit G Thomas, et al.
Molecular Cancer Therapeutics|August 24, 2023
Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath TumorKathryn M Lemberg, Eunus S Ali, Marcela Krecmerova, et al.
Cell Death & Disease|April 28, 2022
Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumorsAshlyn Parkhurst, Sabrina Z Wang, Tyler R Findlay, et al.
Molecular Pharmaceutics|August 2, 2017
Enhanced Brain Delivery of 2-(Phosphonomethyl)pentanedioic Acid Following Intranasal Administration of Its γ-Substituted Ester ProdrugsMichael Nedelcovych, Ranjeet P Dash, Lukáš Tenora, et al.
Frontiers in Pharmacology|October 31, 2025
Mass spectrometry-guided discovery of novel GCPII inhibitor scaffoldsRobyn Wiseman, Ajit G Thomas, John Janiszewski, et al.
Journal of Medicinal Chemistry|September 10, 2019
Discovery of Benzamidine- and 1-Aminoisoquinoline-Based Human MAS-Related G-Protein-Coupled Receptor X1 (MRGPRX1) AgonistsEva Prchalová, Niyada Hin, Ajit G Thomas, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|June 19, 2019
Glutamine Antagonist JHU083 Normalizes Aberrant Glutamate Production and Cognitive Deficits in the EcoHIV Murine Model of HIV-Associated Neurocognitive DisordersMichael T Nedelcovych, Boe-Hyun Kim, Xiaolei Zhu, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Proceedings of the National Academy of Sciences of the United States of America|November 22, 2012
Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosisKristen A Rahn, Crystal C Watkins, Jesse Alt, et al.
Molecular Cancer Therapeutics|October 10, 2019
The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath TumorKathryn M Lemberg, Liang Zhao, Ying Wu, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|March 14, 2019
Correction: JHU-083 selectively blocks glutaminase activity in brain CD11b<sup>+</sup> cells and prevents depression-associated behaviors induced by chronic social defeat stressXiaolei Zhu, Michael T Nedelcovych, Ajit G Thomas, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 22, 2018
JHU-083 selectively blocks glutaminase activity in brain CD11b<sup>+</sup> cells and prevents depression-associated behaviors induced by chronic social defeat stressXiaolei Zhu, Michael T Nedelcovych, Ajit G Thomas, et al.
Molecular Cancer Therapeutics|August 24, 2023
Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath TumorKathryn M Lemberg, Eunus S Ali, Marcela Krecmerova, et al.
Cell Death & Disease|April 28, 2022
Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumorsAshlyn Parkhurst, Sabrina Z Wang, Tyler R Findlay, et al.
Molecular Pharmaceutics|August 2, 2017
Enhanced Brain Delivery of 2-(Phosphonomethyl)pentanedioic Acid Following Intranasal Administration of Its γ-Substituted Ester ProdrugsMichael Nedelcovych, Ranjeet P Dash, Lukáš Tenora, et al.
Frontiers in Pharmacology|October 31, 2025
Mass spectrometry-guided discovery of novel GCPII inhibitor scaffoldsRobyn Wiseman, Ajit G Thomas, John Janiszewski, et al.
Journal of Medicinal Chemistry|September 10, 2019
Discovery of Benzamidine- and 1-Aminoisoquinoline-Based Human MAS-Related G-Protein-Coupled Receptor X1 (MRGPRX1) AgonistsEva Prchalová, Niyada Hin, Ajit G Thomas, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|June 19, 2019
Glutamine Antagonist JHU083 Normalizes Aberrant Glutamate Production and Cognitive Deficits in the EcoHIV Murine Model of HIV-Associated Neurocognitive DisordersMichael T Nedelcovych, Boe-Hyun Kim, Xiaolei Zhu, et al.
Pageof 8